Pith. sign in

Pith Integrity · Reference Change Desk · events-only

Reference changes

See every place this corpus cites a work that was later retracted, corrected, withdrawn, or placed under expression of concern: exact quote, event source, and what happened next. No model judges the citation.

A notice on this page means a citing paper's bibliography includes a work with a published scholarly-record event. It is not a judgment on the citing paper.

Scoped to citing paper 2509.04939 · clear

01Events with corpus notices

Correction Crossref 1 open · 1 total
Corrigendum to: “Measurement of the <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si1.gif" overflow="scroll"> <mml:mi>t</mml:mi> <mml:mover accent="true"> <mml:mrow> <mml:mi>t</mml:mi> </mml:mrow> <mml:mrow> <mml:mo stretchy="false">¯</mml:mo> </mml:mrow> </mml:mover> </mml:math> production cross-section using eμ events with b-tagged jets in pp collisions at <mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" altimg="si2.gif" overflow="scroll"> <mml:msqrt> <mml:mi>s</mml:mi> </mml:msqrt> <mml:mo>=</mml:mo> <mml:mn>13</mml:mn> </mml:math>  TeV with the ATLAS detector” [Phys. Lett. B 761 (2016) 136–157]

DOI 10.1016/j.physletb.2016.08.019 · event 2017-09-21 · event page · JSON

02One-hop citation notices (secondary index)

Correction Crossref Open
The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors

cites 10.1016/s0140-6736(19)32591-7 · ref [25] · event 2021-06-10 · 2509.04939 · event page · DOI 10.1016/s0140-6736(19)32591-7

Raw extraction · bibliography line

Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE -048): a randomised, open -label, phase 3 study. Lancet. 2019;394(10212):1915-1928. doi:10.1016/S0140-6736(19)32591-7
Correction Crossref Open
The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors

cites 10.1016/s0140-6736(19)32591-7 · ref [25] · event 2020-01-23 · 2509.04939 · event page · DOI 10.1016/s0140-6736(19)32591-7

Raw extraction · bibliography line

Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE -048): a randomised, open -label, phase 3 study. Lancet. 2019;394(10212):1915-1928. doi:10.1016/S0140-6736(19)32591-7
Correction Crossref Open
The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors

cites 10.1016/s0140-6736(19)32591-7 · ref [25] · event 2020-02-21 · 2509.04939 · event page · DOI 10.1016/s0140-6736(19)32591-7

Raw extraction · bibliography line

Burtness B, Harrington KJ, Greil R, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE -048): a randomised, open -label, phase 3 study. Lancet. 2019;394(10212):1915-1928. doi:10.1016/S0140-6736(19)32591-7
Correction Crossref Open
The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors

cites iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics · ref [3] · event 2019-04-30 · 2509.04939 · event page · DOI 10.1016/s1470-2045(17)30074-8

Raw extraction · bibliography line

Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol . 2017;18(3):e143 -e152. doi:10.1016/S1470-2045(17)30074-8
Correction Crossref Open
The SChISM study: Cell-free DNA size profiles as predictors of progression in advanced carcinoma treated with immune-checkpoint inhibitors

cites Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types · ref [4] · event 2025-03-03 · 2509.04939 · event page · DOI 10.1136/jitc-2024-010311

Raw extraction · citation context

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol . 2017;18(3):e143 -e152. doi:10.1016/S1470-2045(17)30074-8 4. Gandara DR, Agarwal N, Gupta S, et al. Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types. J Immunother Cancer. 2025;13(2):e010311. doi:10.1136/jitc-2024-010311 5. Ngo P, Cooper WA, Wade S, et al. Why PD -L1 expression varies between studies of lung cancer: …

Parser render (TeX stripped for reading; raw above is the evidence)

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol . 2017;18(3):e143 -e152. doi:10.1016/S1470-2045(17)30074-8 4. Gandara DR, Agarwal N, Gupta S, et al. Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types. J Immunother Cancer. 2025;13(2):e010311. doi:10.1136/jitc-2024-010311 5. Ngo P, Cooper WA, Wade S, et al. Why PD -L1 expression varies between studies of lung cancer: …